|
|
|
|
| |
|
| |
|
|
pCommuniqué de presse 26 avril 2021/p
pAu cours de la période du 19/04/2021 au 25/04/2021, une filiale indirecte de la société Econocom Group SE à savoir BIS Bedrijfs Informatie Systemen B.V. a acquis un total de 857 981 actions Econocom Group pour un prix total de 2 958 359,77 euros./p
pAu 26 avril 2021, BIS Bedrijfs Informatie Systemen B.V. détient... See more |
|
|
|
| |
|
| |
|
|
https://mb.cision.com/Public/18595/logo/86a99b25f755738d_org.jpg
Acquisitions of own shares and disposals of own shares
Brussels Belgium, 23 April 2021 =E2=80=93 20:00 CEST =E2=80=93 regulate=
d information
Acquisitions of own shares
In accordance with article 8:4 of the Royal Decree of 29 April 2019 executi=
ng the Belgian Code on Companies and Associations, UCB SA/NV... See more |
|
|
|
| |
|
| |
|
|
https://mb.cision.com/Public/18595/logo/86a99b25f755738d_org.jpg
UCB to Present 12 Abstracts on Bimekizumab at AAD VMX 2021
Brussels, Belgium =E2=80=93 April 23, 2021, 16:15 CEST =E2=80=93 UCB, a glo=
bal biopharmaceutical company, today announced that 12 abstracts on bimekiz=
umab, an investigational IL17A and IL17F inhibitor, in the treatment of a=
dults with moderate to severe... See more |
|
|
|
| |
|
| |
|
|
https://mb.cision.com/Public/18595/logo/86a99b25f755738d_org.jpg
The New England Journal of Medicine Publishes Results from Two Bimekizum=
ab Phase 3 Studies in Moderate to Severe Plaque Psoriasis
=C2=B7 Today, two manuscripts published back to back detail the full result=
s from the BE RADIANT and BE SURE studies, comparing the efficacy and safet=
y of bimekizumab to secukinumab and... | |
Search :
